The WuXi Biologics facility in Dundalk is a state-of-the-art biopharmaceuticals contract manufacturing facility and one of the world’s largest facilities using single-use bioreactor technology.

The Dundalk facility is a state-of-the-art ‘factory of the future’ using the novel approach to the commercial biomanufacturing of biologics-based medicines pioneered by WuXi Biologics. This is the very latest in biopharmaceutical manufacturing technology where single-use bioreactors are used for batch-production of products as opposed to traditional stainless-steel vessels on a round-the-clock basis. This results in higher productivity and significantly lower costs for cell culture-based biopharmaceuticals manufacturing.

Using large volume, single-use bioreactors greatly enhances commercial manufacturing potential by allowing not only scale-out of capacity but also scale-up and flexibility for supplying multiple products and customer needs.

The facility in Dundalk is a critical component of the company’s global biomanufacturing network. It is a multi-product facility for manufacturing monoclonal antibodies (mAb) and recombinant proteins, offering clients an innovative global entry point to bring new biological therapies to market.

Having achieved full national and international cGMP regulatory accreditation, WuXi Biologics has now begun commercial production of several vitally important medicines on behalf of clients around the world.

Areas of focus WuXi Biologics, Ireland

- Manufacture of monoclonal antibodies (mAb) and recombinant proteins
- State-of-the-art cGMP drug substance manufacturing plant
- Single-use bioreactors process set up

End-to-End Solutions Enabling Our Global Partners

**C** Contract Services
- Target Selection
- Reagent/Protein Generation & Assay Development
- Antibody Generation
- Complex Biologics Engineering (e.g., ADC)
- Lead ID & Optimization
- Developability Assessment
- Characterization (e.g., PK, PD, Efficacy & Exploratory Tox)
- PCC Selection
- Regulatory Support

**R**
- Cell Line Engineering
- Assay Development
- Process Development
- Drug Product Development
- DS & DP Scale Up
- Cell Banking & Characterization
- Pilot Scale Manufacturing
- Viral Clearance
- Late-stage Dev & PC/PV
- IND & BLA Filing Support

**D**
- DS GMP Manufacturing
- DP GMP Manufacturing
- QC Lot Release & Stability
- Global Dual Source Support

**O**
- One partner with expertise in all areas
Why Ireland?

Ireland has become a global hotspot for investment in biopharmaceuticals over the past 10 years.

These investments have been attracted by Ireland’s world class research facilities and supportive business environment which are well-recognised for fostering innovation and growth.

Alongside this, Ireland supports a thriving supply chain ecosystem of activity generated by the expansive clusters of multinational and indigenous biopharmaceuticals businesses operating around the country.

Ireland’s National Institute for Bioprocessing Research and Training (NIBRT) for example provides a global centre of excellence for training and research in bioprocessing. It offers world-class facilities and expertise to ensure the sector has a sustainable supply of suitably trained staff.

Ireland’s exemplary record in working with both national and international regulators - the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) among others, is another key ingredient in making Ireland an ideal location for global biopharmaceutical manufacturing.

Dundalk’s strategic location on the M1 motorway links it directly to Ireland’s two largest cities, Dublin and Belfast, which are both less than 90 kilometres distance. In addition, some of Ireland’s towns, including Dundalk, Drogheda, Swords, Balbriggan, Newry, Monaghan, Cavan and Armagh, are within easy reach. Dundalk also provides easy access to three international airports serving 290 destinations, an intercity rail service, motorway connectivity and deep seaports.

WuXi Biologics, Dundalk, Ireland

WuXi Biologics is located on the M1 Corridor, offering employees coastal and uncongested urban living, competitive house prices and a great work life balance.

- Excellent residential areas and amenities locally and in the surrounding areas
- Equal opportunities available for all
- A dynamic employee profile
- World class training
- Positive work culture and excellent work life balance to allow you enjoy all Dundalk has to offer
WuXi Biologics is committed to transparency when it comes to environmental stewardship, social responsibility and corporate governance.

An ESG taskforce has been established to develop a WuXi Biologics Dundalk approach to sustainability initiatives including ways to support our emissions from the site and within the community. That taskforce currently comprises a cross functional team of professionals who are constantly seeking ways of ensuring that all aspects of WuXi Biologics Ireland and its activities are sustainable.

In parallel to our Environmental and Sustainability programme of measures aimed at reducing our carbon and energy usage, we are making efforts to address and promote the Social and Governance aspects of our business which include the following education and awareness training around our ESG focus; the WiSTEM programme to promote increased participation of women in science, technology, engineering, and maths; the WeCare program which focuses on our culture, team engagement, and wellbeing; and our Corporate Social Responsibility team’s support for initiatives and activities with the community.

WuXi Biologics is a leading global biologics CRDMO offering end-to-end solutions which empower partners to discover, develop and manufacture biologics from concept to commercial manufacturing for the benefit of patients worldwide. It currently supports nearly 600 companies worldwide, including all top 20 pharmaceutical companies.

The company’s business model is based around the contract development and manufacturing of biologics for some of the world’s largest biopharma companies. WuXi Biologics deploys a ‘Global Dual Sourcing’ manufacturing strategy through its facilities in the United States, Ireland, Germany, Singapore and China. To effectively meet the rapidly growing needs of its partners, WuXi Biologics estimates that its total planned biomanufacturing capacity will exceed 588,000 litres by 2026, ensuring a robust global supply capability chain to provide biologics of premier quality worldwide.

WuXi Biologics is unique in that it operates the world’s only open-access biologics technology production platform. This offers end-to-end solutions to partner organisations who use it to discover, develop and manufacture biologics medicines from initial concept through to commercial manufacturing. As a fully-integrated contract manufacturing platform company, WuXi Biologics provides its partners with the advanced capabilities, cutting-edge technologies and comprehensive solutions to enable them to develop innovative biologics medicine.

The company’s discovery platforms include systems for producing large numbers of identical antibodies, technology to connect proteins with the genetic information that encodes them and full analytical and assay development capabilities. With world-class research expertise, state-of-the-art technologies and access to proprietary methodology, WuXi Biologics can generate antibodies for a multitude of target conditions and help partner companies identify candidate drugs for the full spectrum of disease areas.

**588 integrated projects**

**12,000+ employees worldwide including 4,000 scientists**

**30+ facilities in five countries**

**Almost 600 global partners**

2023 ISPE Facility of the Year (FOYA) Awards Winner

2023 Invest in Ireland Awards Winner

2023 Irish Construction Excellence Awards Winner

Our Global Presence

www.wuxibiologics.com | info@wuxibiologics.com

Dr Chris Chen (CEO of WuXi Biologics), Brendan McGrath (Ireland Site Head and VP Manufacturing, WuXi Biologics Dundalk) with WuXi Biologics employees during the cheque presentation following participation in the 100km in 30 Days challenge for Breast Cancer Ireland.